Related Experiment Video

Updated: May 16, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

Plasma catestatin level in patients with acute myocardial infarction and its correlation with ventricular remodelling

Lei Meng1, Jie Wang, Wen-hui Ding

  • 1Department of Cardiology, Peking University First Hospital, Beijing 100034, PR China. menglei@medmail.com.cn

Postgraduate Medical Journal
|December 11, 2012
PubMed

Insights

Plasma catestatin levels increase after acute myocardial infarction (AMI). Early catestatin elevation is linked to heart function and may predict long-term ventricular remodelling in AMI patients.

Area of Science:

  • Cardiology
  • Biomarkers
  • Myocardial Infarction Research

Background:

  • Prognosis prediction in acute myocardial infarction (AMI) relies on evaluating ventricular remodelling and functional recovery.
  • Understanding biomarkers associated with these changes is crucial for patient outcomes.

Purpose of the Study:

  • To measure plasma catestatin levels in patients with AMI.
  • To investigate the relationship between plasma catestatin and cardiac function.
  • To explore the association between plasma catestatin and left ventricular remodelling (LVR).

Main Methods:

  • Prospective recruitment of 58 patients with ST-segment elevation myocardial infarction (STEMI) within 12 hours of symptom onset.
  • Plasma catestatin measured by ELISA; echocardiography performed at baseline and 3 months for LVR assessment.
  • Comparison of catestatin levels between patients and controls, and over time post-AMI.

Main Results:

  • Plasma catestatin was elevated on admission and peaked in the first week post-AMI, returning to normal by 3 months.
  • Admission catestatin correlated with anterior AMI and left ventricular ejection fraction (LVEF).
  • Patients with LVR showed higher catestatin levels on admission and days 3-7 compared to those without LVR.

Conclusions:

  • Plasma catestatin levels rise following AMI, with early increases correlating with anterior AMI and LVEF.
  • Elevated post-AMI catestatin may indicate progressive ventricular remodelling at 3 months.
  • Catestatin shows potential as a biomarker for assessing cardiac function and remodelling post-myocardial infarction.
Abstract

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...